European Commission logo
English English
CORDIS - EU research results
CORDIS

A revolutionary shape memory alloy-based disposable device for bladder cancer removal

Project description

Special cover to minimise bladder cancer recurrence

Bladder cancer is the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. In Europe, a total of 118 000 new cases and 52 000 deaths are estimated annually. While treatment depends on how advanced the cancer is, there is a high risk of tumour recurrence. The U-TURBT project developed an innovative disposable device (by the same name) to cover and seal the bladder portion affected by the tumour. The cover stops tumour cell spillage and dissemination, minimising the risk of recurrence. It will also be upgraded to permit bladder tumour resection and extrication.

Objective

Bladder cancer represents the 9th most common malignancy worldwide and the 4th most common in men. Globally approximately 2.5M people suffer from it, with 420,000 newly diagnosed cases each year. In Europe, a total of 118,000 new cases and 52,000 deaths are estimated annually. With population growth and ageing, the absolute incidence of bladder cancer might be further escalating.
Despite the increasing incidences, the current treatments remain ineffective. The gold standard Trans-Urethral Resection of Bladder Tumour (TURBT) has up to 61% risk of tumour recurrence due to incomplete removal or tumour cell implantation during the procedure.
CML introduces U-TURBT, an innovative disposable device for the treatment of bladder cancer. By covering and sealing the portion of bladder affected by the tumour, it avoids tumour cell spillage and dissemination. By minimising the risk of recurrence, U-TURBT improves patients’ health and quality of life, and cuts down the expenses of the healthcare providers relative to additional treatments.
During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, CML will upgrade the device to permit en bloc bladder tumour resection and extrication. Large scale clinical trial will then be initiated for obtaining CE mark as a medical device

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

CAMBRIDGE MECHATRONICS LIMITED
Net EU contribution
€ 50 000,00
Address
UNIT 17, BLOCK 6 THE WESTBROOK CENT
CB4 1YG CAMBRIDGE
United Kingdom

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
East of England East Anglia Cambridgeshire CC
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00